Nasus Pharma Ltd. (NSRX)

Nasus Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Net Income	-5.86	-1.53	-1.05	-1.71
Stock-Based Compensation	0.45	0.01	0.04	0.02
Other Adjustments	0.97	0.46	-0.14	-0.33
Changes in Accounts Payable	0.15	-0.01	-0.12	0.15
Changes in Accrued Expenses	-0.18	0.32	0.27	0.15
Changes in Other Operating Activities	-0.45	0.08	-0.04	0.5
Operating Cash Flow	-4.92	-0.67	-1.03	-1.21
Capital Expenditures	-0.01	-	-	-
Purchases of Investments	-3	-	-	-
Other Investing Activities	-	-	-	-0.16
Investing Cash Flow	-3.01	-	-	-0.16
Short-Term Debt Issued	-	-	0.06	0.5
Net Short-Term Debt Issued (Repaid)	-	-	0.06	0.5
Long-Term Debt Issued	0.44	1	1	0.97
Net Long-Term Debt Issued (Repaid)	0.44	1	1	0.97
Issuance of Common Stock	8.49	-	-	0
Net Common Stock Issued (Repurchased)	8.49	-	-	0
Other Financing Activities	-	-0.23	-	-0.23
Financing Cash Flow	8.92	0.77	1.06	1.24
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.01	-0	0.01	-0.01
Net Cash Flow	0.98	0.1	0.04	-0.14
Free Cash Flow	-4.93	-0.67	-1.03	-1.21
Free Cash Flow Per Share	-0.62	-0.09	-0.15	-0.18
Levered Free Cash Flow	-5.92	-0.13	0.12	0.56
Unlevered Free Cash Flow	-5.4	-0.68	-1.03	-1.24

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q